Stock Market Impact: Shares slipped 0.43% to NZD 27.53 after the release, pressured by U.S. tariff and NZD currency headwinds despite strong earnings.
Listed Companies and Sectors: Fisher & Paykel Healthcare Ltd delivered FY2026 operating revenue NZD 2.3 bn (+14% YoY) and NPAT NZD 468.5 m (+24% YoY); gross margin rose to 63.7%, underscoring robustness of the medical‑device/health‑care equipment sector.
Investment Flows: The company announced a fully‑imputed final dividend of NZD 0.33 per share (total NZD 0.52, 65% payout), which may support investor interest; no specific FDI/FPI commentary.
Interest Rates, Inflation, Liquidity: Operating cash flow increased 21% to NZD 663 m, indicating solid liquidity; no direct interest‑rate or inflation policy discussion.
Fiscal or Monetary Policy: No fiscal/monetary measures disclosed; the discussion highlighted a 90 bps tariff drag on gross margin and NZD 21 m hedging loss, as well as assumed 10% U.S. tariff rate for FY2027 guidance.
